Basel Medical Group LTD (BMGL) — SEC Filings

Overview

Basel Medical Group LTD (BMGL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 24, 2026: Basel Medical Group Ltd filed a 6-K on March 24, 2026, which is a routine report for foreign private issuers to disclose material information. This specific filing, with accession number 0001493152-26-012252, indicates the company is fulfilling its ongoing reporting obligations to the SEC. For inves

Sentiment Summary

Across 22 filings, the sentiment breakdown is: 1 bearish, 19 neutral, 2 mixed. The dominant filing sentiment for Basel Medical Group LTD is neutral.

Filing Type Overview

Basel Medical Group LTD (BMGL) has filed 21 6-K, 1 20-F with the SEC between Feb 2025 to Mar 2026.

Filings by Year

2026 · 2025

Recent Filings (22)

• 6-K Filing — 6-K · Mar 30, 2026
• Basel Medical Group Files Routine 6-K, Maintains SEC Compliance — 6-K · Mar 24, 2026
  Basel Medical Group Ltd filed a 6-K on March 24, 2026, which is a routine report for foreign private issuers to disclose material information. This specific fil
• Basel Medical Receives Nasdaq Delinquency Notice — 6-K · Dec 1, 2025 Risk: medium
  Basel Medical Group Ltd. filed a Form 6-K on December 1, 2025, reporting the receipt of a delinquency notification from Nasdaq. The company's principal executiv
• BMGL's Future Hinges on Key Surgeons Amidst Fierce Competition — 20-F · Nov 18, 2025 Risk: high
  Basel Medical Group Ltd (BMGL) filed its 20-F for the fiscal year ended June 30, 2025, highlighting its dependence on key medical practitioners and exposure to
• Basel Medical Group Appoints New Chief Commercial Officer — 6-K · Aug 21, 2025 Risk: low
  Basel Medical Group Ltd (Nasdaq: BMGL) announced the appointment of Mr. Tan Boon Chye (Darren) as its Chief Commercial Officer, effective August 15, 2025. Mr. T
• Basel Medical Group Ltd Loses Chief Partnership Officer — 6-K · Aug 13, 2025 Risk: medium
  Basel Medical Group Ltd (Nasdaq: BMGL) announced on August 13, 2025, that its Group Chief Partnership Officer, Mr. Vincent Teo, has submitted his resignation. T
• Basel Medical Group Halts BTC Digital Asset Acquisition — 6-K · Jul 18, 2025 Risk: medium
  Basel Medical Group Ltd announced on July 17, 2025, that it is putting on hold its acquisition of BTC Digital Asset. The company filed this report on July 18, 2
• Basel Medical Group Appoints New Auditor — 6-K · Jul 2, 2025 Risk: low
  Basel Medical Group Ltd (Nasdaq: BMGL) announced on June 30, 2025, the appointment of NLA DFK Assurance PAC as its new independent registered public accounting
• Basel Medical Secures Lock-Up Waiver for Fundraising — 6-K · Jun 26, 2025 Risk: medium
  Basel Medical Group Ltd announced on June 26, 2025, that it has obtained a waiver of its lock-up agreement. This waiver is a crucial step that potentially allow
• Basel Medical Group Ltd Files 6-K with Financials — 6-K · Jun 18, 2025 Risk: low
  Basel Medical Group Ltd filed a Form 6-K on June 18, 2025, reporting unaudited consolidated financial statements and management's discussion for the six months
• Basel Medical Group Ltd. Files May 2025 Report — 6-K · Jun 3, 2025 Risk: low
  Basel Medical Group Ltd. filed a Form 6-K on June 3, 2025, reporting for the month of May 2025. The filing includes a press release dated May 29, 2025. The comp
• Basel Medical Group Signs Master Supply Agreement — 6-K · May 22, 2025 Risk: low
  On May 20, 2025, Basel Medical Group Ltd. (Nasdaq: BMGL) announced that its subsidiary, Basel Medical Group Pte Ltd, entered into a Master Supply Agreement with
• Basel Medical Group Plans $1B Bitcoin Acquisition — 6-K · May 16, 2025 Risk: high
  Basel Medical Group Ltd announced on May 16, 2025, a strategic initiative to acquire up to US$1.0 billion in Bitcoin (BTC). This move signifies a significant sh
• Basel Medical Completes Bethesda Acquisition — 6-K · Apr 30, 2025 Risk: low
  On April 11, 2025, Basel Medical Group Ltd (Nasdaq: BMGL), through its subsidiary BMGPL, entered into a sale and purchase agreement to acquire all ordinary shar
• Basel Medical Group CEO Resigns, Interim Appointed — 6-K · Apr 21, 2025 Risk: medium
  On April 15, 2025, Basel Medical Group Ltd (Nasdaq: BMGL) announced the resignation of Raymond Cheung as Chief Executive Officer and a director. The board has a
• Basel Medical Acquires Bethesda Medical — 6-K · Apr 11, 2025 Risk: medium
  On April 11, 2025, Basel Medical Group Ltd (Nasdaq: BMGL), through its subsidiary BMGPL, announced the acquisition of Bethesda Medical Pte. Ltd. from Silkroute
• Basel Medical Group Appoints New Director — 6-K · Apr 4, 2025 Risk: low
  On April 4, 2025, Basel Medical Group Ltd appointed Mr. Keng Leong Fung (Raymond Fung) as a director to its Board. Mr. Fung was nominated by Rainforest Capital
• Basel Medical Group Ltd to follow BVI governance over Nasdaq rules — 6-K · Mar 25, 2025 Risk: medium
  Basel Medical Group Ltd, incorporated in the British Virgin Islands, has notified Nasdaq of its intention to follow BVI corporate governance practices instead o
• Basel Medical Group Ltd IPO Underwriting Agreement — 6-K · Mar 19, 2025 Risk: low
  On February 24, 2025, Basel Medical Group Ltd entered into an underwriting agreement with Cathay Securities, Inc., as representative for the underwriters. This
• Basel Medical Group Ltd Closes IPO — 6-K · Mar 6, 2025 Risk: medium
  Basel Medical Group Ltd announced the closing of its initial public offering (IPO) on February 26, 2025. The company sold 2,205,000 ordinary shares as part of t
• Basel Medical Group Ltd Closes Initial Public Offering — 6-K · Mar 3, 2025 Risk: medium
  Basel Medical Group Ltd announced the closing of its initial public offering (IPO) on March 3, 2025. The company entered into an underwriting agreement with Cat
• Basel Medical Group Ltd Announces IPO Underwriting Agreement — 6-K · Feb 28, 2025 Risk: medium
  On February 24, 2025, Basel Medical Group Ltd entered into an underwriting agreement with Cathay Securities, Inc., acting as the representative for the underwri

Risk Profile

Risk Assessment: Of BMGL's 20 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Dr. Darren Yen Feng Chhoa
• Tan Boon Chye (Darren)
• Vincent Teo
• Darren Yen Feng Chhoa
• Raymond Cheung
• Keng Leong Fung
• Raymond Fung

Industry Context

Basel Medical Group Ltd operates within Singapore's competitive healthcare market, facing pressure from both private and public providers. The industry is characterized by a reliance on specialist medical practitioners and brand reputation. Trends likely include increasing adoption of technology, evolving regulatory landscapes, and potential shifts in patient demand influenced by factors like public health and economic conditions.

Top Tags

ipo (4) · acquisition (3) · compliance (2) · regulatory-filing (2) · foreign-issuer (2) · management-change (2) · resignation (2) · press-release (2) · foreign-private-issuer (2) · healthcare (2)

Key Numbers

• Ordinary shares outstanding: 18,785,750 — As of June 30, 2025, indicating the current share count.
• Bitcoin Acquisition Target: US$ 1.0 Billion — Represents the total planned investment in Bitcoin.
• Ordinary Shares Sold: 2,205,000 — Number of shares issued in the IPO
• IPO Closing Date: February 26, 2025 — Date the initial public offering was completed

Frequently Asked Questions